Investing Now Could Prove Beneficial For CytomX Therapeutics Inc. (NASDAQ: CTMX) – Marketing Sentinel
Home  »  Science   »  Investing Now Could Prove Beneficial For CytomX Th...

Investing Now Could Prove Beneficial For CytomX Therapeutics Inc. (NASDAQ: CTMX)

During the last session, CytomX Therapeutics Inc. (NASDAQ:CTMX)’s traded shares were 1.23 million, with the beta value of the company hitting 0.65. At the end of the trading day, the stock’s price was $1.80, reflecting an intraday gain of 5.26% or $0.09. The 52-week high for the CTMX share is $7.53, that puts it down -318.33 from that peak though still a striking 16.67% gain since the share price plummeted to a 52-week low of $1.50. The company’s market capitalization is $121.39M, and the average intraday trading volume over the past 10 days was 0.81 million shares, and the average trade volume was 1.02 million shares over the past three months.

CytomX Therapeutics Inc. (CTMX) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.70. CTMX has a Sell rating from 0 analyst(s) out of 9 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 1 suggest Overweight, and 8 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.37.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

CytomX Therapeutics Inc. (NASDAQ:CTMX) trade information

CytomX Therapeutics Inc. (CTMX) registered a 5.26% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 5.26% in intraday trading to $1.80 this Wednesday, 06/22/22, hitting a weekly high. The stock’s 5-day price performance is 6.51%, and it has moved by 11.11% in 30 days. Based on these gigs, the overall price performance for the year is -74.03%. The short interest in CytomX Therapeutics Inc. (NASDAQ:CTMX) is 3.8 million shares and it means that shorts have 4.1 day(s) to cover.

The consensus price target of analysts on Wall Street is $10.75, which implies an increase of 83.26% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6.00 and $16.00 respectively. As a result, CTMX is trading at a discount of -788.89% off the target high and -233.33% off the low.

CytomX Therapeutics Inc. (CTMX) estimates and forecasts

Statistics show that CytomX Therapeutics Inc. has underperformed its competitors in share price, compared to the industry in which it operates. CytomX Therapeutics Inc. (CTMX) shares have gone down -72.09% during the last six months, with a year-to-date growth rate less than the industry average at -10.77% against 0.60. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to shrink -23.30% this quarter and then drop -8.60% in the quarter after that. In the rating firms’ projections, revenue will increase 9.10% compared to the previous financial year.

Revenue for the current quarter is expected to be $19.07 million as predicted by 9 analyst(s). Meanwhile, a consensus of 9 analyst(s) estimates revenue growth to $19.22 million by the end of Sep 2022. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $16.86 million and $18.08 million respectively. In this case, analysts expect current quarter sales to grow by 13.10% and then jump by 6.30% in the coming quarter.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 4.30%. While earnings are projected to return -82.90% in 2022, the next five years will return -0.90% per annum.

CTMX Dividends

CytomX Therapeutics Inc. is due to release its next quarterly earnings between February 22 and February 28. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

CytomX Therapeutics Inc. (NASDAQ:CTMX)’s Major holders

CytomX Therapeutics Inc. insiders own 1.32% of total outstanding shares while institutional holders control 88.17%, with the float percentage being 89.34%. Point72 Asset Management, L.P. is the largest shareholder of the company, while 178 institutions own stock in it. As of Dec 30, 2021, the company held over 6.3 million shares (or 9.64% of all shares), a total value of $27.29 million in shares.

The next largest institutional holding, with 6.03 million shares, is of RTW Investments LP’s that is approximately 9.22% of outstanding shares. At the market price on Dec 30, 2021, these shares were valued at $26.11 million.

Also, the Mutual Funds coming in first place with the largest holdings of CytomX Therapeutics Inc. (CTMX) shares are Vanguard Total Stock Market Index Fund and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF. Data provided on Dec 30, 2021 indicates that Vanguard Total Stock Market Index Fund owns about 1.83 million shares. This amounts to just over 2.79 percent of the company’s overall shares, with a $7.91 million market value. The same data shows that the other fund manager holds slightly less at 1.78 million, or about 2.73% of the stock, which is worth about $8.2 million.

Leave a Comment

Your email address will not be published.

On Key

Related Posts

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]